This week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate ...
Practice of medicine could fundamentally change with these types of therapies,” said CEO Jaideep Dudani, of T cell engagers ...
As for GBS itself, this neurological ailment can be severe, attacking nerves and warranting hospitalisation for weeks or ...
On Tuesday, January 7, the FDA announced it would now be requiring GSK and Pfizer’s RSV vaccines to hold warnings of a risk ...
Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...
Regulators say, however, the benefits of vaccination with Abrysvo and Arexvy in preventing respiratory syncytial virus ...
Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback